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CLINICAL TRIALS AND OBSERVATIONS
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A total of 186 patients with primary myelo-
fibrosis (PMF) were genotyped for
JAK2V617F at diagnosis aimed at analyz-
ing the correlation of mutational status
and mutated allele burden with out-
come variables, including time to anemia,
leukocytosis, leukopenia, thrombocy-
topenia, massive splenomegaly, leuke-
mia, and with overall survival. A total of
127 JAK2V617F-mutated patients (68% of
whole series) were divided in quartiles of
V617F allele burden. After a median
follow-up of 17.2 months, 23 patients died,
15 because of leukemia. A JAK2V617F
mutated status did not impact on the rate
of leukemia transformation or overall sur-
vival. Patients in the lower quartile had
shorter time to anemia and leukopenia
and did not progress to large spleno-
megaly. Furthermore, survival was sig-
nificantly reduced in the lower quartile
compared with upper quartiles and JAK2
wild-type patients. In multivariate analy-
sis, factors associated with reduced sur-
vival were age, a blast count more than
1%, and a JAK2V617F burden within first
quartile. Causes of death in the lower
quartile were represented mainly by sys-
temic infections. We conclude that a low
JAK2V617F allele burden at diagnosis is
preferentially associated with a myelo-
depletive rather than myeloproliferative
phenotype and represents an indepen-
dent factor associated with shortened
survival in patients with PMF. (Blood.
2009;114:1477-1483)
Introduction
Sixty percent of patients with primary myelofibrosis (PMF) present
an acquired recurrent mutation located in exon 14 of JAK2
(JAK2V617F)1-4; an additional 8% to 10% harbor a mutation at
codon 515 in MPL, ie, W515L/K/A.5-7 These mutations represent a
major criterion for diagnosis according to the 2008 World Health
Organization classification of myeloid neoplasms8; however, they
are not specific of this disorder and are shared by other Philadelphia
chromosome-negative myeloproliferative neoplasms, which in-
clude polycythemia vera (PV), essential thrombocythemia (ET),
and refractory anemia with ring sideroblasts and thrombocytosis.
A JAK2V617F mutated genotype as well as different V617F
allele burden have been variably associated with unique hemato-
logic and clinical characteristics in patients with PV or ET.9 In
particular, it has been shown that increasing amounts of V617F
allele corresponded to a more pronounced myeloproliferative
phenotype favoring higher hemoglobin level and leukocyte count,
delineating a “continuum” of the 2 disorders.10 Furthermore, the
higher the mutational burden, the higher the risk of presenting
aquagenic pruritus, developing splenomegaly, having thrombosis,
requiring cytotoxic therapy, or transforming to post-PV/post-ET
myelofibrosis.9
On the contrary, information in the setting of PMF is limited to a
few studies that generally included patients genotyped at different
times from diagnosis and used qualitative or semiquantitative
assays11-13; therefore, biases resulting from disease duration and
previous therapy on hematologic and clinical phenotype and on
patients’ outcome, as well as the effects of different mutated allele
load, could not be adequately controlled. Only one recent study
used a quantitative assay for measuring allele burden and evaluat-
ing its clinical correlates.14 The aim of current study was to analyze
the prognostic relevance of JAK2V617F mutational status and of
mutated allele burden in a population of newly diagnosed patients
with PMF.
Methods
Patients
This study involved 186 patients with a diagnosis of PMF satisfying the
2008 World Health Organization criteria.15 Patients were eligible to enter
the study if they had a blood sample collected for JAK2V617F genotyping
at the time of diagnosis or within the following 6 months, before institution
of any treatment. Patients who had MPL mutated were excluded from the
analysis. Rules for collection, storage, and use of blood samples, and for
data analysis, were approved by the local Institutional Review Board of the
Azienda Ospedaliera Universitaria Careggi, and all subjects provided
informed consent. This study was conducted in accordance with the
Declaration of Helsinki. Conventional cytogenetic analysis was performed
according to standard techniques using unstimulated bone marrow aspirates
collected during diagnostic workup. Results were reported following the
International System for Human Cytogenetic Nomenclature. According to
recent literature,16,17 we considered as “favorable” cytogenetics the sole
deletion of 13q, 20q, trisomy 9, as well as a normal diploid karyotype;
“unfavorable” cytogenetics included the presence of abnormalities of
chromosome 5 or 7 as well as complex karyotype with more than
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3 abnormalities. No abnormality of chromosome 17, considered “very
unfavorable,”16 was found in this series.
Purpose of the study
Our primary aim was to determine the correlations, if any, between a
JAK2V617F mutated status or the burden of V617F allele and the rate of
major outcome events, which included overall survival and transformation
to acute leukemia. We also determined whether the mutated status or the
burden of JAK2 mutated allele correlated with specific laboratory parame-
ters or clinical features, which included red blood cell indexes, leukocyte or
platelet count, serum lactate dehydrogenase levels, peripheral blood (PB)
CD34 cell count, percentage of PB blasts, splenomegaly, constitutional
symptoms, and the ranking of patients according to the Dupriez et al18 or the
Cervantes et al prognostic scores.19 Constitutional symptoms included loss
of 10% or more of body weight in the last 6 months, night sweats, or
unexplained fever. Splenomegaly was measured as centimeters from the left
costal margin (LCM); we considered 2 groups of patients who presented a
spleen enlargement smaller or greater than 15 cm from LCM, respectively.
Determination of JAK2V617F allele burden
Measurement of JAK2V617F allele burden was performed in genomic
DNA purified from granulocytes. Granulocytes were separated from PB by
differential centrifugation over a Ficoll-Paque gradient, and contaminating
erythrocytes were removed by hypotonic lysis; DNA was purified using the
QIAmp DNA blood kit (QIAGEN GmbH) and quantified with NanoDrop
technology.
The burden of mutated allele was measured by a quantitative real-time
polymerase chain reaction (PCR) assay, using 40 ng DNA.20 PCR
amplification and detection were performed on an ABI Prism 7300 analyzer
(Applied Biosystems) using the following cycling conditions: 10 minutes at
95°C followed by 50 cycles of 15 seconds at 95°C and 60 seconds at 60°C.
Primer sequence was as follows: forward primer 5-TTATGGACAACAGT-
CAAACAACAAT-3; allele G reverse primer 5-TTTACTTACTC-
TCGTCTCCACAGtC3 and allele T reverse primer 5-TTTACTTACT-
CTCGTCTCCACAGtA-3 (lowercase nucleotides are locked nucleic
acid–modified). 6-carboxyfluorescein–labeled minor groove binder probe
sequence was: 5-CTTGCTCATCATACTTGC-3. All samples were ana-
lyzed in triplicate, and the amount of JAK2V617F allele was calculated by
comparison with serial dilutions of mutated and wild-type DNA or with
cloned JAK2 plasmids. The mean of triplicate CT determinations
(CTJAK2V617F-CTJAK2WT) was used to calculate the percentage of mutated
allele. Positive and negative controls were included in each assay; inter-
and intra-assay variation was 3% and 5%, respectively.
Statistical analysis
The JAK2 mutated allele burden was considered as an ordered categorical
variable based on the following groups: 0% (JAK2 wild-type patients),
1% to 25%, greater than 25% to 50%, greater than 50% to 75%, and greater
than 75%.
We used the 2 or Fisher exact test (2  2 table) or 2 test for trend
(larger contingency table), where appropriate, to compare the variables
among the different patient groups that had been categorized according to
mutational status or mutated allele burden. The analysis of continuous
variables among the groups was performed using the Mann-Whitney U test
(2 groups) or Kruskal-Wallis test with the use of Dunn method for multiple
comparison. Kaplan-Meier analysis and the log-rank test were used to
estimate overall survival. Cox regression models were used to perform
multivariate analysis. A P value of less than .05 was considered to indicate
statistical significance; all tests were 2-tailed. Data were processed using
the SPSS software.
Results
A total of 186 patients with a diagnosis of PMF were genotyped
with a quantitative assay for JAK2V617F mutation in granulocyte
DNA collected within 6 months from diagnosis, provided that no
treatment, except for transfusional support, had been delivered in
the meantime. A total of 127 patients were JAK2V617F-positive,
giving an overall frequency of 68.3%; the median value of V617F
allele burden was 54% (range, 5%-100%; Table 1). The distribution
of mutated patients according to the V617F allele burden, shown in
Table 2, corresponded to overall frequencies of 13.3% in the first
quartile, 33.8% in the second, 24.4% in the third, and 28.3% in the
fourth. Neither a JAK2V617F mutated status nor the categorized
burden of mutated allele was correlated with age or sex (Tables
1-2). Results of cytogenetic analysis at diagnosis were available in
94 patients (50.5% of total population); 77 patients (81.9%) had
favorable abnormalities (58 of whom presented a normal diploid
karyotype), whereas 17 (18.1%) had unfavorable cytogenetic
abnormalities (Table 3). Of the 26 informative patients who were
JAK2 wild-type, 6 patients (23.0%) had unfavorable cytogenetic
abnormalities compared with 11 of 68 (16.2%) of those who were
JAK2V617F mutated (P  .021).
Association of V617F mutated genotype or mutated allele
burden with hematologic and clinical characteristics
At presentation, patients harboring a JAK2V617F mutation had
significantly higher hemoglobin level (P  .001), leukocyte count
(P  .009), and platelet count (P  .02) compared with those
without the mutation (Table 1). Accordingly, the proportion of
anemic patients (hemoglobin  100 g/L) at presentation was
significantly lower among JAK2V617 mutated patients compared
with wild-types (22% vs 44%; P  .03). By considering the
different categories of patients in dependence of the V617F allele
burden, we observed a statistically significant correlation with
leukocytosis (P  .03) and an almost significant trend for higher
hemoglobin level (P  .05; Table 2). On the contrary, we found no
impact of the mutated genotype or the mutated allele burden on
other hematologic parameters, including peripheral blasts more
than 1%, lactate dehydrogenase level, and circulating CD34 cells.
JAK2V617F mutated and wild-type patients did not differ from
each other regarding the presence of a palpable splenomegaly
greater than 15 cm from LCM or of constitutional symptoms;
however, considering the group of mutated patients only, the
frequency of those with large splenomegaly or constitutional
symptoms increased significantly in relation to V617F allele
burden (P  .003 and P  .04, respectively; Table 2).
To analyze whether the JAK2V617F mutational status corre-
lated with prognostic scoring systems, we evaluated the distribu-
tion of patients in the different risk categories of the Dupriez et al18
or Cervantes et al19 score; however, because of the relatively low
number of patients in the quartiles of V617F allele burden, we
abstained from performing subgroup analysis. We observed that the
number of JAK2V617F mutated patients in the low-risk category of
the Dupriez et al18 scoring system was significantly greater
compared with unmutated patients (P  .017), possibly the result
of the higher hemoglobin level found in mutated patients; on the
other hand, the distribution of patients in the 4 risk categories of the
Cervantes et al19 score was independent of JAK2V617F muta-
tional status.
Association of V617F mutated genotype or mutated allele
burden with disease progression
To investigate the impact of JAK2V617F mutational status or
categorized V617F allele burden on parameters associated with
disease progression, we calculated the time elapsing from diagnosis
1478 GUGLIELMELLI et al BLOOD, 20 AUGUST 2009  VOLUME 114, NUMBER 8 For personal use only.2009. 
 at UNIVERSITA DEGLI STUDI FIRENZE BIBLIOTECA BIOMEDICA on August 21,www.bloodjournal.orgFrom 
to hematologic and clinical outcome events, which included:
changes in hematologic parameters not the result of cytoreductive
therapy (anemia, defined as an hemoglobin steadily  100 g/L;
leukopenia, as a leukocyte count  4  109/L; leukocytosis, as a
leukocyte count  25  109/L; thrombocytopenia, as a platelet
count  100  109/L); the development of massive splenomegaly
(considered as a spleen enlarged  15 cm from LCM in patients
who presented smaller spleen size at diagnosis); and the evolution
to acute leukemia. In the comparison of JAK2V617F mutated vs
unmutated patients, we found that time to anemia or time to
leukopenia was significantly longer (P  .017 and P  .001,
respectively) in those harboring the mutation, whereas the statisti-
cal significance was not attained for other outcome events (Figure
1). The relative risk (RR) associated with a JAK2 wild-type status
was 1.64 (95% confidence interval [CI], 1.04-2.58) in case of
anemia and 3.43 (95% CI, 1.59-7.41) in case of leukopenia
compared with JAK2V617F mutated patients. In particular, we
observed that a JAK2V617F mutated status did not represent a risk
factor for transformation to acute leukemia (Figure 1); the RR was
1.57 (95% CI, 0.55-4.41) in JAK2V617F mutated compared with
wild-type patients.
The relevance of different V617F allele burden on those
outcomes was also evaluated. We found that patients in the lower
quartile had significantly shorter time to anemia (P  .02) and
Table 1. Hematologic and clinical features at presentation in patients with PMF according to their JAK2 V617F mutational status
Feature JAK2 WT JAK2 V617F P
No. 59 127
Median age, y (range) 57 (21-88) 62 (21-90) .47
Median follow-up, mo (range) 27 (1-185) 29 (1-237) .72
Females, no. (%) 18 (30.5) 51 (40.1) .23
Median white blood cell count, 109/L (range) 7.70 (1.9-90.78) 10.10 (3.01-16.15) .009*
Median hemoglobin, g/L (range) 106 (46-190) 128.5 (54-180) .001*
Median platelets, 109/L (range) 251 (8.0-1488) 386 (42-2011) .02*
Blast 1, no. (%) 16 (30.5) 38 (29.9) .89
Median LDH, U/L (range) 704 (197-2970) 718 (120-2981) .96
Median CD34 cell, % (range) 0.25 (0.0-6.6) 0.19 (0-34) .65
Median CD34 cell, 109/L (range) 18.84 (0.0-3417) 22 (0.3-800) .77
Median JAK2V617F allele burden (range) — 54 (5-100) —
Splenomegaly 15 cm from LCM, no. (%) 11 (18.6) 26 (19.7) .89
Constitutional symptoms, no. (%) 15 (25.4) 38 (29.9) .15
Leukemia transformation, no. (%) 6 (10.1%) 9 (7.1) .45
Deaths, no. (%) 8 (13.5) 15 (11.8) .64
Lille score, no. (%)
0 22 (37.2) 80 (63.0) .017*
1 26 (44.0) 38 (30.0)
2 11 (18.8) 9 (7.0)
IWG-MRT score, no. (%)
low 18 (30.5) 47 (37.0) .60
Intermediate-1 15 (25.5) 32 (25.2)
Intermediate-2 16 (27.1) 20 (15.7)
High 10 (16.9) 28 (22.1)
— indicates not applicable; and IWG-MRT, International Working Group for Myelofibrosis Research and Treatment.
*Statistically significant difference.
Table 2. Hematologic and clinical features at presentation in patients with PMF according to their JAK2 V617F allele burden
Feature
JAK2V617F allele burden (%)
P1-25 26-50 51-75 76-100
No. 17 43 31 36
Median age, y (range) 58 (38-90) 63 (28-90) 65 (28-77) 60.31 (21-86) .72
Median follow-up, mo (range) 16 (1-46) 24 (1-84) 26 (3-101) 45 (1-237) .001*
Females, no. (%) 4 (23.5) 21 (48.8) 12 (38.7) 14 (38.9) .40
Median JAK2 V617F allele burden (range) 15.5 (5-25) 41 (27-50) 66 (52-75) 90.5 (77-100) —
Median white blood cell count, 109/L (range) 10.26 (3.01-26.85) 9.47 (3.73-106.15) 9.40 (3.70-40.0) 13.40 (3.40-40.60) .03*
Median hemoglobin, g/L (range) 128 (54-173) 122 (61-175) 134 (70-171) 136 (56-180) .05*
Median platelets, 109/L (range) 380.5 (45-1392) 386 (49-1089) 410 (42-1088) 379 (75-2011) .95
Median LDH, U/L (range) 712 (193-2981) 745 (162-2497) 600 (120-1958) 700 (225-2166) .83
Blast1, no. (%) 10 (58.8) 9 (33.3) 7 (35) 12 (50) .21
Median CD34 cell, % (range) 0.23 (0-3.1) 0.19 (0.01-34) 0.09 (0.02-3.43) 0.25 (0.02-1.32) .98
Median CD34 cell, 109/L (range) 22.8 (1.4-244) 17.54 (0.26-800) 7.06 (2.72-476) 43.0 (3.0-130.0) .93
Splenomegaly 15 cm from LCM, no. (%) 1 (5.8) 7 (16.2) 8 (25.8) 9 (25.0) .003*
Constitutional symptoms, % 4 (23.5) 11 (25.6) 6 (19.3) 17 (47.2) .04*
Leukemia transformation, no. (%) 0 4 (9.3) 2 (6.4) 3 (8.3) .09
Deaths, no. (%) 6 (35.3) 7 (16.3) 1 (3.2) 1 (2.8) .007*
— indicates not applicable; and LCM, left costal margin.
*Statistically significant difference.
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leukopenia (P  .004) compared with upper quartiles (Figure 2);
the corresponding RR values were 2.11 (95% CI, 1.1-4.43) for
anemia and 6.84 (95% CI, 1.9-24.59) for leukopenia. We also
found that time to large splenomegaly was significantly shorter in
patients of the upper quartiles compared with the lower quartile
(P  .02); only one of 17 patients in the lower quartile (5.8%)
developed large splenomegaly during the follow-up compared with
16.2%, 25.8%, and 25.0% in the other quartiles (Figure 3; Table 2).
On the other hand, there was no significant difference in the time to
leukemia progression among the 4 quartiles (P  .07); however, it
must be noted that none of the patients in the lower burden group
evolved to leukemia (Figure 3; Table 2).
Association of V617F mutated genotype or mutated allele
burden with disease outcome
After a median follow-up of 17.2 months, there were 23 patients
(12.3%) who died, accounting for 13.5% and 11.8% of the JAK2
wild-type and JAK2V617F mutated, respectively (P  .64; Table
1). Transformation to acute leukemia was the reason of death in
15 of them (65% of all deaths), accounting for 10.1% and 7.1% of
JAK2 wild-type and JAK2V617F mutated patients, respectively
(P  .078). Duration of survival was similar in JAK2 wild-type and
JAK2V617F mutated patients (P  .73; Figure 3A). However,
when we analyzed JAK2V671F mutated patients after stratification
according to the burden of V617F allele, we found that survival
was significantly shorter in the lower quartile compared with upper
quartiles (P  .001, Figure 3B) as well as to JAK2 wild-type
patients (P  .006; Figure 3A). The percentage of patients in the
lower quartile who died was as high as 35.3% compared with
16.3%, 3.2%, and 2.8% in upper quartiles, respectively (P  .007,
Table 2). Causes of death in the lower quartile were represented by
systemic infections or sepsis (n  5) and multiorgan failure
(n  1), whereas no case of leukemia transformation was observed.
The distribution of patients with favorable or unfavorable cytoge-
netic abnormalities according to their V617F allele burden is
presented in Table 3; there was no statistically significant preferen-
tial clustering of unfavorable cytogenetic abnormalities in any of
the different allele burden categories (P  .073, 2 test for trend).
Table 3. Distribution of cytogenetic abnormalities in patients with PMF according to their JAK2 V617F allele burden
JAK2V617F allele burden,
percentage
Patients with cytogenetic information
available Cytogenetic categories
No. Percentage of total Favorable, no. (%) Unfavorable, no. (%)
0 26 44.0 20 (76.9) 6 (23.0)
1-25 8 47.0 7 (87.5) 1 (12.5)
26-50 17 39.5 15 (88.2) 2 (11.7)
51-75 17 54.8 12 (70.5) 5 (29.4)
76-100 26 72.2 23 (88.4) 3 (11.5)
Total 94 50.5 77 (81.9) 17 (18.1)
Favorable cytogenetic category included sole deletion of 13q or 20q or trisomy 9, and a normal karyotype; unfavorable cytogenetic category included abnormalities of
chromosome 5 and/or 7 and complex cytogenetics.
Figure 1. Kaplan-Meier analysis of the time to developing hematologic and clinical outcome events in PMF patients according to their JAK2V617F mutational
status. The plots show time to anemia (hemoglobin  100 g/L), leukopenia (leukocytes  4  109/L), leukocytosis ( 25  109/L), thrombocytopenia ( 100  109/L), large
splenomegaly ( 15 cm from left costal margin in patients presenting smaller spleen at diagnosis), and time to leukemic transformation. P values are shown inside each box.
WT indicates JAK2 wild-type patients; V617F, JAK2V617F mutated patients.
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Variables that were associated with overall survival in univari-
ate and multivariate analysis are listed in Table 4. Age, PB blast
count, and a lower V617F allele burden maintained their significant
association with survival in multivariate analysis; of note, there
was an almost significant association of hemoglobin level (hazard
ratio  0.60; 95% CI, 0.36-1.01; P  .051) with survival.
Discussion
PMF is associated with poorer prognosis compared with other
classic BCR/ABL-negative chronic myeloproliferative neoplasms
because of a substantial reduction of life expectancy21 in the order
of 31% compared with sex- and age-adjusted control population.22
However, survival may range from a few months to an excess of a
decade, especially in younger patients.23-25 Therefore, identification
of variables associated with prognosis is of considerable impor-
tance for driving therapeutic decisions, particularly in the case of
hematopoietic stem cell transplantation, which is the only poten-
tially curative therapeutic approach, yet still burdened by consider-
able morbidity and mortality.26 Three main prognostic score
systems have been developed. One is the so-called Lille score,
which includes anemia and leukopenia or leukocytosis (leuko-
cytes  4  109/L or  30  109/L, respectively) as covariates to
identify 3 distinct prognostic groups.18 The second one, developed
at the Mayo Clinic, introduced thrombocytopenia ( 100  109/L)
and monocytosis ( 109/L) as additional variables resulting in an
improved discriminatory power of the Lille score.27 More recently,
the International Working Group for Myelofibrosis Research and
Treatment developed a new prognostic score system that included
age ( 65 years), presence of constitutional symptoms, anemia
(hemoglobin  100 g/L), leukocytosis ( 25  109/L), and blood
blasts more than 1% and discriminated 4 categories of patients
with significantly different median survival in the range of 27 to
135 months.19
The discovery of the JAK2V617F mutation and its association
with distinct hematologic and clinical characteristics prompted
further research to assessing the predictive value of mutational
status for the most common complications of PV or ET, ie, vascular
events, and for prognosis and survival more in general. The latter
aspect is particularly relevant for PMF because survival in PV or
ET may be only slightly reduced compared with the normal
population. The purpose of present study was to evaluate the
consequence of JAK2V617F mutational status and V617F mutated
allele burden on disease outcome in a population of newly
diagnosed patients with PMF. Similar to observations made in PV
or ET, also in this series of PMF patients, we found statistically
significant association of the JAK2V617F mutated status with a
more pronounced myeloproliferative phenotype favoring raised
hemoglobin level and leukocyte count; accordingly, the time to
developing anemia or leukopenia during the follow-up was signifi-
cantly longer, and conversely the time to develop leukocytosis
significantly shorter, in mutated patients. These findings were
generally in agreement with results from the English11 and
GIMEMA13 groups and at variance with the Mayo Clinic series12,14
in which hemoglobin levels were not significantly modified by the
presence of mutation.14 We also found that patients presenting
anemia at diagnosis were significantly less frequent among
JAK2V617F mutated than wild-type, and this probably accounted
for more mutated patients to be included within the low-risk
category according to Lille score system. However, the main
outcome events of the study, namely, overall survival and leukemia
transformation, were not appreciably different in the 2 categories of
patients defined by their JAK2V617F genotype. These results are in
line with the study from the Mayo Clinic14 but in disagreement with
the results of the English study,11 which reported a hazard ratio of
shortened survival of 3.3 (95% CI, 1.26-8.68) in patients harboring
the V617F allele.11 In addition, in the GIMEMA study,13 overall
survival was not influenced by a JAK2V617F mutated status,
although a higher rate of leukemic transformation was observed;
the reason for these discrepancies is not obvious and might be
generically ascribed to series variability. Therefore, a conclusion of
the present study is that a JAK2V617F mutated status per se does
not reflect in a poorer prognosis in PMF.
Figure 2. Kaplan-Meier analysis of the time to develop-
ing hematologic and clinical outcome events in
JAK2V617F mutated PMF patients categorized ac-
cording to quartiles of mutated allele burden. The
plots show time to anemia, leukopenia, large spleno-
megaly, and leukemic transformation in the 4 quartiles of
JAK2V617F allele burden. P values are shown inside
each box. Quartiles of V617F allele burden were as
follows: first, 1% to 25%; second, greater than 25% to
50%; third, greater than 50% to 75%; fourth, greater than
75% to 100%.
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However, the fact that overall survival in JAK2V617F
mutated patients was similar to wild-type patients notwithstand-
ing their higher hemoglobin level, which is considered as one
major factor influencing survival in PMF, suggested possible
heterogeneity within the category of mutated patients. Similarly,
a correlation of JAK2V617F mutated status with outcome
events, including thrombosis, in patients with PV resulted
evident only after stratification according to their burden of
mutated allele at diagnosis.28,29 Therefore, in this study, we used
a sensitive real-time PCR approach to stratifying PMF patients
in quartiles of burden of mutated allele at presentation. We
found that patients included in the lower quartile showed
significantly shorter progression time to anemia, leukopenia,
and conversely longer time to large splenomegaly, compared
with upper quartiles. More importantly, we found a striking
difference in overall survival that was significantly reduced in
patients of the lower quartile compared not only with upper
quartiles but also with JAK2 wild-type patients. Reduced
survival was not the result of leukemic transformation (no
patient in the lower quartile evolved to leukemia) but mainly to
systemic infections. Thus, patients in the lower quartiles
apparently died because of the consequences of bone marrow
failure, as indirectly suggested by the shorter time to developing
leukopenia. The poorer survival of patients harboring low
JAK2V617F allele burden was first described in a study from the
Mayo Clinic,14 although, at variance with present results, also
leukemia-free survival was reportedly shorter in patients in-
cluded in the lower quartile. Because the follow-up time of the 2
series is comparable, differences in patient characteristics
and/or of treatments used could unpredictably underlie these
discrepancies. Furthermore, an additional variable might have
been represented by the different source of genomic DNA used
for quantification of JAK2V617F burden, that is, unfractionated
whole bone marrow cells in the Mayo Clinic study compared
with purified granulocytes in the current study.
In conclusion, results of this study validate and extend a recent
report14 and point to a low JAK2V617F allele burden at diagnosis
as a strong surrogate marker associated with shortened survival in
PMF; at present, the biologic mechanisms underlying this correla-
tion remain fully to be established. One additional implication of
our findings is that, although JAK2 genotyping is recommended in
the diagnostic workup of suspected PMF according to the WHO
classification, a quantitative rather than a qualitative assay would
be more appropriate. In this regard, an initiative of the European
Leukemia Net working group is undergoing with the aim to
harmonize different JAK2V617F quantitation methods; indeed, a
recent multicenter study found that several of the quantitative
assays described in the literature produced discrepant results.30
Indeed, the finding of a low JAK2V617F allele burden at diagnosis
would point to a poorer prognosis that cannot be appropriately
recognized by current score systems. This information might drive
early therapeutic decisions, involving the use of stem cell transplan-
tation in younger patients and/or patient inclusion in trials with
investigational drugs. However, we acknowledge that a preferential
clustering of low-allele burden subjects in the high-risk category of
the International Working Group for Myelofibrosis Research and
Treatment scoring system might have been missed because of the
relatively small size of our patient population. Therefore, we
suggest the opportunity of a large prospective study on a well-
characterized population of patients and with a standardized
JAK2V617F quantitation method, which might ideally find place
within international consortia and potentially provide definite
information within a relatively short time.
Acknowledgments
This study was supported by Istituto Toscano Tumori, Ente Cassa
di Risparmio di Firenze, Ministero della Universita` e Ricerca
(PRIN projects), and Universita` di Firenze (institutional funds,
ex-60%). A.P. was supported by Associazione Italiana per le
Leucemie, Firenze.
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Table 4. Cox proportional hazard models of factors independently
predictive of overall survival of PMF patients
Variable HR (95% CI) P
Univariate
Age 1.12 (1.07-1.18)  .001
Female sex 7.58 (1.76-32.63) .007
Hemoglobin level 0.77 (0.66-0.89) .001
Leukocyte count 1.04 (1.02-1.05)  .001
PB blasts  1% 1.30 (1.16-1.45)  .001
Splenomegaly ( 15 cm
LCM) 2.41 (1.09-5.29) .028
V617F burden  25% 0.09 (0.03-0.32)  .001
Multivariate
Age 1.21 (1.08-1.34) .001
PB blasts  1% 1.57 (1.13-2.16) .022
V617F burden  25% 0.023 (0.002-0.24) .002
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